These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Naringenin-4'-glucuronide as a new drug candidate against the COVID-19 Omicron variant: a study based on molecular docking, molecular dynamics, MM/PBSA and MM/GBSA. Cobre AF; Maia Neto M; de Melo EB; Fachi MM; Ferreira LM; Tonin FS; Pontarolo R J Biomol Struct Dyn; 2024 Jul; 42(11):5881-5894. PubMed ID: 37394802 [TBL] [Abstract][Full Text] [Related]
13. In silico screening of the effectiveness of natural compounds from algae as SARS-CoV-2 inhibitors: molecular docking, ADMT profile and molecular dynamic studies. Mohammed Ali HSH; Altayb HN; Bayoumi AAM; El Omri A; Firoz A; Chaieb K J Biomol Struct Dyn; 2023 Apr; 41(7):3129-3144. PubMed ID: 35253618 [TBL] [Abstract][Full Text] [Related]
14. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent. Basit A; Ali T; Rehman SU J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773 [TBL] [Abstract][Full Text] [Related]
15. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2. Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM J Infect Public Health; 2021 Feb; 14(2):227-237. PubMed ID: 33493919 [TBL] [Abstract][Full Text] [Related]
16. Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery. Arunkumar M; Gunaseelan S; Kubendran Aravind M; Mohankumar V; Anupam P; Harikrishnan M; Siva A; Ashokkumar B; Varalakshmi P J Biomol Struct Dyn; 2022; 40(19):8961-8988. PubMed ID: 34014150 [TBL] [Abstract][Full Text] [Related]
17. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2. Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070 [TBL] [Abstract][Full Text] [Related]
18. Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2. Naik SR; Bharadwaj P; Dingelstad N; Kalyaanamoorthy S; Mandal SC; Ganesan A; Chattopadhyay D; Palit P J Biomol Struct Dyn; 2022 Sep; 40(15):6921-6938. PubMed ID: 33682632 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation. Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061 [TBL] [Abstract][Full Text] [Related]
20. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation. Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]